Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta-Analysis. [PDF]
EJHaemABSTRACT Background Immunosuppressive therapy (IST) is standard first‐line treatment for severe aplastic anaemia (AA) in patients ineligible for allogeneic transplantation. Thrombopoietin receptor agonists (TPO‐RAs) are increasingly added to IST to improve haematologic recovery, but long‐term safety remains uncertain.
Ashrafi E +5 more
europepmc +2 more sources
Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series
Hematology/Oncology and Stem Cell Therapy, 2020 Thrombocytopenia is a relatively common complication following allogeneic hematopoietic stem cell transplantation and is associated with increased bleeding, transfusion requirements, chronic graft-versus-host disease, and all-cause mortality.
Guido Lancman +2 more
doaj +1 more source
Plasma thrombopoietin levels as additional tool in clinical management of thrombocytopenic neonates
Platelets, 2020 Plasma thrombopoietin (Tpo) levels distinguish thrombocytopenia resulting from increased platelet destruction or decreased platelet production. We investigated whether measuring plasma Tpo levels in thrombocytopenic newborns is of diagnostic value to ...
Leendert Porcelijn +5 more
doaj +1 more source
Pathophysiology, classification, and complications of common asymptomatic thrombocytosis in newborn infants [PDF]
Clinical and Experimental Pediatrics, 2022 We frequently encounter newborn infants with thrombocytosis in the neonatal intensive care unit. However, neonatal thrombocytosis is not yet fully understood.
Ga Won Jeon
doaj +1 more source
Advances in management of pediatric chronic immune thrombocytopenia: a narrative review [PDF]
Journal of Yeungnam Medical Science, 2023 Immune thrombocytopenia (ITP) is a disease in which thrombocytopenia occurs because of immune-mediated platelet destruction and decreased platelet production.
Jae Min Lee
doaj +1 more source
Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
EMBO Molecular Medicine, 2017 Congenital amegakaryocytic thrombocytopenia (CAMT) is an inherited disorder characterized at birth by thrombocytopenia with reduced megakaryocytes, which evolves into generalized bone marrow aplasia during childhood.
Alessandro Pecci +12 more
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2022 C3G is a Rap1 guanine nucleotide exchange factor that controls platelet activation, aggregation, and the release of α-granule content. Transgenic expression of C3G in platelets produces a net proangiogenic secretome through the retention of ...
Luis Hernández-Cano +17 more
doaj +1 more source
Asian Journal of Transfusion Science, 2022 INTRODUCTION: Thrombopoietin (TPO) being the major regulator of megakaryopoiesis is expected to show a compensatory increase in immune thrombocytopenia (ITP), however, it is not so observed.
Gurleen Oberoi +5 more
doaj +1 more source
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
Frontiers in Oncology, 2021 The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its ...
Jerry L. Spivak, Alison R. Moliterno
doaj +1 more source
Thrombopoietin and platelet aggregation in patients with stable coronary artery disease
Platelets, 2017 Thrombopoietin (TPO) may facilitate platelet activation and aggregation. However, data on the impact of TPO on platelet aggregation in patients with stable coronary artery disease (CAD) are scarce.
Sanne Bøjet Larsen +5 more
doaj +1 more source